{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:35:34Z","timestamp":1793889334305,"version":"4.8.0"},"reference-count":31,"publisher":"Massachusetts Medical Society","issue":"9","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2018,8,30]]},"DOI":"10.1056\/nejmoa1803550","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T17:01:33Z","timestamp":1535562093000},"page":"811-822","source":"Crossref","is-referenced-by-count":726,"title":["Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors"],"prefix":"10.1056","volume":"379","author":[{"given":"Johnny","family":"Mahlangu","sequence":"first","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Paz-Priel","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Negrier","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Niggli","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elisa","family":"Mancuso","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Schmitt","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kempton","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Dhalluin","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael U.","family":"Callaghan","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Bujan","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne I.","family":"Adamkewicz","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Asikanius","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallia G.","family":"Levy","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kruse-Jarres","sequence":"additional","affiliation":[{"name":"From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universit\u00e4tsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann\u2013La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106073442307"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.06.002"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1042\/BA20010082"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01750.x"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12270"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S44694"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6680"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13365"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479"},{"key":"e_1_3_4_12_2","unstructured":"Hemlibra (emicizumab) summary of product characteristics. Basil Switzerland: F. Hoffmann\u2013La Roche 2018 (http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004406\/WC500244743.pdf)."},{"key":"e_1_3_4_13_2","unstructured":"Hemlibra (emicizumab) prescribing information. South San Francisco CA: Genentech 2017 (https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf)."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","unstructured":"Young G Sidonio RF Liesner R et al. HAVEN 2 updated analysis: multicenter open-label phase 3 study to evaluate efficacy safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors. Presented at the annual meeting of the American Society of Hematology Atlanta December 9\u201312 2017. abstract.","DOI":"10.1182\/blood.V130.Suppl_1.85.85"},{"key":"e_1_3_4_16_2","first-page":"231","article-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use.","volume":"48","year":"1997","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. Int Dig Health Legis 1997;48:231-234.11656783","journal-title":"Int Dig Health Legis"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_3_4_18_2","article-title":"A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A.","author":"Yoneyama K","year":"2017","unstructured":"Yoneyama K, Schmitt C, Kotani N, et al. A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A. Clin Pharmacokinet 2017 December 6 (Epub ahead of print).29214439","journal-title":"Clin Pharmacokinet"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_3_4_20_2","unstructured":"Kruse-Jarres R Oldenburg J Santagostino E et al. Bleeding events and safety outcomes in persons with haemophilia A (PwHA) without inhibitors: non-interventional study (NIS) from a real-world setting. Presented at the 11th annual congress of the European Association for Haemophilia and Allied Disorders Madrid February 7\u20139 2018. abstract."},{"key":"e_1_3_4_21_2","first-page":"115","article-title":"Validation of the Haemophilia-Specific Quality of Life Questionnaire for adult patients with haemophilia (Haem-A-QoL).","volume":"90","author":"von Mackensen S","year":"2005","unstructured":"von Mackensen S, Gringeri A, Ravera S, et al. Validation of the Haemophilia-Specific Quality of Life Questionnaire for adult patients with haemophilia (Haem-A-QoL). Haematologica 2005;90:Suppl 2:115-116.","journal-title":"Haematologica"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12642"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12259"},{"key":"e_1_3_4_24_2","first-page":"724","article-title":"Factor VIII inhibitor testing using a validated chromogenic Bethesda assay in HAVEN 1 (BH29884), a phase 3 trial of emicizumab in persons with hemophilia A with inhibitors.","volume":"1","author":"Adamkewicz JI","year":"2017","unstructured":"Adamkewicz JI, Schmitt C, Asikanius E, et al. Factor VIII inhibitor testing using a validated chromogenic Bethesda assay in HAVEN 1 (BH29884), a phase 3 trial of emicizumab in persons with hemophilia A with inhibitors. Res Pract Thromb Haemost 2017;1:Suppl 1:724-724.","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_3_4_25_2","unstructured":"Mancuso ME Callaghan MU Kruse-Jarres R et al. Emicizumab prophylaxis in adolescent\/adult patients with hemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study. Presented at the annual meeting of the American Society of Hematology Atlanta December 9\u201312 2017. abstract."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14022"},{"key":"e_1_3_4_28_2","first-page":"26","article-title":"In vitro thrombin generation testing and in vivo venous stasis model for assessing the pro-coagulant effects of FVIII, emicizumab, rFVIIa, and aPCC.","volume":"23","author":"Adamkewicz JI","year":"2017","unstructured":"Adamkewicz JI, Muto A, Soeda T, Suzuki S, Kitazawa T. In vitro thrombin generation testing and in vivo venous stasis model for assessing the pro-coagulant effects of FVIII, emicizumab, rFVIIa, and aPCC. Haemophilia 2017;23:Suppl 2:26-26.","journal-title":"Haemophilia"},{"key":"e_1_3_4_29_2","unstructured":"Pipe S Jim\u00e9nez-Yuste V Shapiro A et al. Emicizumab subcutaneous dosing every 4 weeks is safe and efficacious in the control of bleeding in persons with haemophilia A with and without inhibitors \u2014 results from the phase 3 HAVEN 4 study. Presented at the 2018 world congress of the World Federation of Hemophilia Glasgow United Kingdom May 20\u201324 2018. abstract."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708483"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708538"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804419"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1803550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:50:02Z","timestamp":1711486202000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1803550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,8,30]]}},"alternative-id":["10.1056\/NEJMoa1803550"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa1803550","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,30]]}}}